🔗 Share this article

While the US proceeds with unprecedented revisions to its immunization recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 shots during the pandemic and has focused upon possible deaths following COVID-19 vaccination in her brief time at the FDA.

Planned Overhauls to Childhood Immunization Schedule

Health officials were set to announce sweeping revisions to the childhood vaccination calendar recently, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US at odds with many the international standard with no evidence for benefit. The planned update has been postponed until the new year.

Instead of the director of the vaccine center, Høeg is listed to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this year.

A New Direction at the Agency

Høeg's temporary position could signify a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for ending certain pediatric immunization guidelines in the US to become more similar to the Danish model, a nation with nationalized medicine and a population approximately the size of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – usually the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Qualifications

Høeg has no obvious background in medication creation, regulation or management, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for leading the CDER, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a sizeable institution. She lacks background in drug approvals.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who led the center have had.”

CDER has an immense workload at the FDA, the former commissioner pointed out.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and every single one need to be supervised,” she explained. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership element to the role, which manages more than 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” she added.

Official Statement and Controversial Policies

Regarding inquiries about Dr. Høeg's credentials and whether this appointment represents more teamwork among FDA leaders on vaccines, a representative said that the “questions stem from incorrect presumptions”.

“This background is consistent with the duties of her position,” the official stated, citing the period Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s controversial expedited review system, a contentious one-day therapy clearance system that allegedly concerned her predecessors. “How are these drugs being picked for this voucher program? Who takes the choices?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards laxer oversight of all drugs, except for immunizations.”

Documented Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if concerning, history, some experts observe. She released a analysis using unverified public submissions to estimate the frequency of myocarditis following COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the new administration featured altering guidelines for new vaccines and discontinuing “unnecessary” vaccines, she said post-election on a online show. At the FDA, Høeg has according to sources floated the idea of preventing adolescent males from getting COVID-19 vaccines.

“She’s an complete dogmatist who begins with her conclusions and works backwards to accommodate the evidence in a very disingenuous, dishonest fashion,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|